Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SYN-004

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BACKGROUND Infections with Clostridium difficile are a health threat, yet no products are currently licensed for prevention of… Expand
2017
2017
ABSTRACT SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 3
2017
2017
To evaluate an antibiotic inactivation strategy to protect the gut microbiome from antibiotic‐mediated damage. 
2017
2017
P R I M A R Y E N D P O I N T C O N C L U S I O N S The use of intravenous β-lactam antibiotics, including cephalosporins, are an… Expand
2017
2017
Abstract Background Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to… Expand
2016
2016
The gut microbiome, composed of the microflora that inhabit the gastrointestinal tract and their genomes, make up a complex… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
BackgroundSYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2016
2016
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2015
2015
Antibiotics (abx) that are excreted into the intestine, such as ceftriaxone (CRO), can damage the microflora and lead to serious… Expand